These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 11326672

  • 1. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K.
    Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
    [Abstract] [Full Text] [Related]

  • 2. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
    Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK.
    Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 5. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999 Jun; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D, Mazurek S, Henschke P, Mesterharm J, Schildhauer S, Geppert R, Wernecke KD, Possinger K.
    Anticancer Res; 2003 Jun; 23(2A):991-7. PubMed ID: 12820337
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR.
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [Abstract] [Full Text] [Related]

  • 10. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999 Oct; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 11. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
    Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M.
    Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
    [Abstract] [Full Text] [Related]

  • 12. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
    Lüfter D, Richter A, Günther S, Flath B, Akrivakis C, Geppert R, Wernecke KD, Possinger K.
    Anticancer Res; 2000 Jul; 20(6D):5099-105. PubMed ID: 11326676
    [Abstract] [Full Text] [Related]

  • 13. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 14. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR.
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [Abstract] [Full Text] [Related]

  • 15. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
    Oremek GM, Sapoutzis N, Kramer W, Bickeböller R, Jonas D.
    Anticancer Res; 2000 Mar; 20(6D):5095-8. PubMed ID: 11326675
    [Abstract] [Full Text] [Related]

  • 16. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG, Zhang N.
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G.
    Anticancer Res; 1997 Aug; 17(4B):3153-6. PubMed ID: 9329624
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.